Effect of vagus nerve stimulation against generalized seizure and status epilepticus recurrence.
drug-resistant epilepsy
generalized seizure
response rate
status epilepticus
vagus nerve stimulation
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
07
2023
accepted:
25
08
2023
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Vagus nerve stimulation (VNS) is a palliative surgery for drug-resistant epilepsy. The two objectives of this study were to (1) determine the seizure type most responsive to VNS and (2) investigate the preventive effect on status epilepticus (SE) recurrence. We retrospectively reviewed 136 patients with drug-resistant epilepsy who underwent VNS implantation. We examined seizure outcomes at 6, 12, and 24 months following implantation of VNS as well as at the last visit to the Juntendo Epilepsy Center. Univariate analysis and multivariate logistic regression models were used to estimate the prognostic factors. 125 patients were followed up for at least 1 year after VNS implantation. The percentage of patients with at least a 50% reduction in seizure frequency compared with prior to VNS implantation increased over time at 6, 12, and 24 months after VNS implantation: 28, 41, and 52%, respectively. Regarding overall seizure outcomes, 70 (56%) patients responded to VNS. Of the 40 patients with a history of SE prior to VNS implantation, 27 (67%) showed no recurrence of SE. The duration of epilepsy, history of SE prior to VNS implantation and seizure type were correlated with seizure outcomes after VNS implantation in univariate analysis ( Following 125 patients with drug-resistant epilepsy for an average of 69 months, 56% showed at least 50% reduction in seizure frequency after VNS implantation. This study suggests that generalized seizure is the most responsive to VNS, and that VNS may reduce the risk of recurrence of SE. VNS was shown to be effective against generalized seizure and also may potentially influence the risk of further events of SE, two marker of disease treatment that can lead to improved quality of life.
Identifiants
pubmed: 37780707
doi: 10.3389/fneur.2023.1258854
pmc: PMC10540227
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1258854Informations de copyright
Copyright © 2023 Iimura, Suzuki, Mitsuhashi, Ueda, Nishioka, Horikoshi, Nomura, Sugano and Kondo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Childs Nerv Syst. 2023 May 23;:
pubmed: 37219617
Brain. 2003 Nov;126(Pt 11):2447-54
pubmed: 12902313
Dev Med Child Neurol. 2023 Jul 14;:
pubmed: 37448317
J Neurosurg. 2011 Dec;115(6):1248-55
pubmed: 21838505
Epilepsia. 2000 May;41(5):601-9
pubmed: 10802767
Epileptic Disord. 2017 Sep 1;19(3):327-338
pubmed: 28832004
Front Neurol. 2023 Apr 20;14:1172898
pubmed: 37153661
Brain Behav. 2023 Jul;13(7):e3076
pubmed: 37254623
Epilepsia. 2023 Apr;64(4):811-820
pubmed: 36727550
Front Neurol. 2023 Jun 14;14:1195844
pubmed: 37388544
Neurosci Lett. 2018 Feb 22;667:84-91
pubmed: 28011391
Epilepsy Curr. 2021 Mar 10;:1535759721999670
pubmed: 33719651
Epilepsy Behav. 2011 Jan;20(1):57-63
pubmed: 21144802
Neuroimmunomodulation. 2005;12(5):307-9
pubmed: 16166810
Epilepsia. 2009 Dec;50 Suppl 12:56-7
pubmed: 19941527
Seizure. 2020 Dec;83:104-123
pubmed: 33120323
Front Aging Neurosci. 2023 Jul 06;15:1173987
pubmed: 37484689
Acta Neurochir (Wien). 2012 Dec;154(12):2237-40
pubmed: 23086106
J Neurol. 2022 Jun;269(6):2874-2891
pubmed: 35034187
J Neurosurg Pediatr. 2023 Feb 17;31(5):476-483
pubmed: 36805960
Neurosurg Rev. 2014 Oct;37(4):661-8
pubmed: 24838990
Neurology. 2007 Aug 28;69(9):886-93
pubmed: 17724291
Front Neurol. 2023 Jan 06;13:1074997
pubmed: 36686529
J Clin Med. 2022 Dec 19;11(24):
pubmed: 36556153
Eur J Neurol. 2004 Dec;11(12):800-10
pubmed: 15667410
Neuromodulation. 2022 Apr;25(3):327-342
pubmed: 35396068
Epilepsia. 2004 Sep;45(9):1064-70
pubmed: 15329071
Lancet Child Adolesc Health. 2023 Jul;7(7):455-462
pubmed: 37276875
Epilepsia. 2007 Feb;48(2):375-8
pubmed: 17295633
Eur J Neurol. 2012 Sep;19(9):1219-23
pubmed: 22891774
Epilepsy Behav. 2023 May;142:109182
pubmed: 36972642